Neuroaktive

Neuroaktive, a German neurotechnology company, focuses on developing treatments for neurological and psychiatric disorders using transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). Founded in 2008, the firm is a spin-off from the University of Lübeck, where its CEO, Ulrich Schweikard, conducted research in the field of neurology.

The company's technology involves the use of non-invasive brain stimulation techniques to target and treat various neurological conditions, including depression, anxiety, and tinnitus. Neuroaktive's products allow for the precise delivery of these stimulation techniques to specific areas of the brain, with the aim of alleviating symptoms and improving the quality of life for patients.

Research conducted by Neuroaktive and its academic partners has demonstrated the efficacy of tDCS and TMS in treating depression and anxiety. The company's technology has been recognized for its safety, non-invasiveness, and relatively low cost compared to other neurological treatments.

Neuroaktive has received funding from various sources, including government institutions and private investors, to further develop and commercialize its products. The company has established partnerships with medical institutions and research organizations to advance the field of neurotechnology.

Despite some controversy surrounding the effects and long-term efficacy of tDCS and TMS, Neuroaktive continues to invest in research and development, operating under strict regulatory guidelines. As the field of neurotechnology expands, Neuroaktive remains a key player in the development of non-invasive brain stimulation treatments.